You have already completed the test before. Hence you can not start it again.
Test is loading...
You must sign in or sign up to start the quiz.
You have to finish following quiz, to start this quiz:
Results
0 of 1 questions answered correctly
Your time:
Time has elapsed
You have reached 0 of 0 scores, (0)
Categories
Not categorized0%
You have completed the test!
1
Answered
Review
Question 1 of 1
1. Question
1 points
What is 'Tzield', recently in the news?
Correct
Option C is correct.
Tzield is the first drug to delay the onset of Type 1 diabetes. Recently, it has been approved by theUS Food and Drug Administration.
Tzield is a monoclonal antibody injection that is capable of preventing the body’s immune system from mistakenly attacking cells in the pancreas that make insulin. It was developed by drugmakersSanofi and Provention Bio.
The common side effects of this drug are decreased levels of certain white blood cells, rashes and headache. It can be administered to people aging 8 and older, who have early symptoms of type 1 diabetes.
It is capable of delaying the onset of stage 3 type 1 diabetes in adults and in pediatric patients aging 8 years and above who have stage 2 type 1 diabetes.
Type 1 diabetes is a chronic medical condition in which the pancreas produces little to no insulin. It was formerly known as insulin-dependent or juvenile diabetes. While it generally appears in children, teens, and young adults, it is known to occur at any age.
It is rarer than the occurrence of type 2 diabetes. Preventive measures for this chronic condition are unknown. Symptoms include maintaining blood sugar level through regular monitoring, insulin therapy, diet and exercise.
Incorrect
Option C is correct.
Tzield is the first drug to delay the onset of Type 1 diabetes. Recently, it has been approved by theUS Food and Drug Administration.
Tzield is a monoclonal antibody injection that is capable of preventing the body’s immune system from mistakenly attacking cells in the pancreas that make insulin. It was developed by drugmakersSanofi and Provention Bio.
The common side effects of this drug are decreased levels of certain white blood cells, rashes and headache. It can be administered to people aging 8 and older, who have early symptoms of type 1 diabetes.
It is capable of delaying the onset of stage 3 type 1 diabetes in adults and in pediatric patients aging 8 years and above who have stage 2 type 1 diabetes.
Type 1 diabetes is a chronic medical condition in which the pancreas produces little to no insulin. It was formerly known as insulin-dependent or juvenile diabetes. While it generally appears in children, teens, and young adults, it is known to occur at any age.
It is rarer than the occurrence of type 2 diabetes. Preventive measures for this chronic condition are unknown. Symptoms include maintaining blood sugar level through regular monitoring, insulin therapy, diet and exercise.
Live/Online Class